补体激活型供者特异性抗HLA抗体与实体器官移植存活:系统综述与meta分析
该研究通过系统综述与meta分析评估补体激活型抗HLA供者特异性抗体(DSA)与实体器官移植结局的关联,纳入37项研究共7936例受者。结果显示,循环补体激活型抗HLA DSA阳性受者的移植物丢失风险(汇总HR 3.09;95%CI 2.55-3.74,P=0.001)和排斥风险(汇总HR 3.75;95%CI 2.05-6.87,P=0.001)均显著增高。
要点
- 补体激活型抗HLA DSA阳性受者移植物丢失风险为阴性者的3.09倍。
- 补体激活型抗HLA DSA阳性受者排斥风险为阴性者的3.75倍。
- 该抗体检测或有助于个体化无创生物标志物指导的风险分层。
核心结论
- 循环补体激活型抗HLA DSA对实体器官移植存活和排斥风险具有显著不良影响。
- 检测补体激活型抗HLA DSA可能为个体患者层面的无创生物标志物指导风险分层增加价值。
研究设计与样本
- 系统综述与meta分析,检索Medline、Embase、Cochrane和Scopus数据库至2018年1月31日。
- 共识别5861条合格文献,最终纳入37项研究,涉及7936例受者。
- 受者包括肾移植5991例、肝移植1459例、心脏移植370例和肺移植116例。
- 主要结局为移植物丢失,次要结局为移植物排斥。
主要发现
- 补体激活型抗HLA DSA阳性受者移植物丢失风险增高(汇总HR 3.09;95%CI 2.55-3.74,P=0.001;I2=29.3%)。
- 补体激活型抗HLA DSA阳性受者移植物排斥风险增高(汇总HR 3.75;95%CI 2.05-6.87,P=0.001;I2=69.8%)。
- 补体激活型抗HLA DSA与移植物衰竭的关联在所有亚组和敏感性分析中一致。
临床怎么用
- 检测循环补体激活型抗HLA DSA可用于实体器官移植受者的无创风险分层。
- 补体激活型抗HLA DSA阳性受者移植物丢失和排斥风险显著增高,需加强监测。
局限性
- 几乎所有纳入研究为观察性或回顾性设计。
- 肾移植受者比例高于其他实体器官移植受者。
- 探讨移植物排斥的研究数量较少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anti-human leukocyte antigen donor-specific antibodies (anti-HLA DSAs) are recognized as a major barrier to patients' access to organ transplantation and the major cause of graft failure. The capacity of circulating anti-HLA DSAs to activate complement has been suggested as a potential biomarker for optimizing graft allocation and improving the rate of successful transplantations. METHODS AND FINDINGS: To address the clinical relevance of complement-activating anti-HLA DSAs across all solid organ transplant patients, we performed a meta-analysis of their association with transplant outcome through a systematic review, from inception to January 31, 2018. The primary outcome was allograft loss, and the secondary outcome was allograft rejection. A comprehensive search strategy was conducted through several databases (Medline, Embase, Cochrane, and Scopus). A total of 5,861 eligible citations were identified. A total of 37 studies were included in the meta-analysis. Studies reported on 7,936 patients, including kidney (n = 5,991), liver (n = 1,459), heart (n = 370), and lung recipients (n = 116). Solid organ transplant recipients with circulating complement-activating anti-HLA DSAs experienced an increased risk of allograft loss (pooled HR 3.09; 95% CI 2.55-3.74, P = 0.001; I2 = 29.3%), and allograft rejection (pooled HR 3.75; 95% CI: 2.05-6.87, P = 0.001; I2 = 69.8%) compared to patients without complement-activating anti-HLA DSAs. The association between circulating complement-activating anti-HLA DSAs and allograft failure was consistent across all subgroups and sensitivity analyses. Limitations of the study are the observational and retrospective design of almost all included studies, the higher proportion of kidney recipients compared to other solid organ transplant recipients, and the inclusion of fewer studies investigating allograft rejection. CONCLUSIONS: In this study, we found that circulating complement-activating anti-HLA DSAs had a significant deleterious impact on solid organ transplant survival and risk of rejection. The detection of complement-activating anti-HLA DSAs may add value at an individual patient level for noninvasive biomarker-guided risk stratification. TRIAL REGISTRATION: National Clinical Trial protocol ID: NCT03438058.
引用
- Bouquegneau A, Loheac C, Aubert O, et al. Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis. PLoS Med. 2018. PMID: 29799874. doi:10.1371/journal.pmed.1002572
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。